These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 9874849)

  • 1. Clinical status and optimal use of rituximab for B-cell lymphomas.
    McLaughlin P; White CA; Grillo-López AJ; Maloney DG
    Oncology (Williston Park); 1998 Dec; 12(12):1763-9; discussion 1769-70, 1775-7,. PubMed ID: 9874849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group.
    Tobinai K; Kobayashi Y; Narabayashi M; Ogura M; Kagami Y; Morishima Y; Ohtsu T; Igarashi T; Sasaki Y; Kinoshita T; Murate T
    Ann Oncol; 1998 May; 9(5):527-34. PubMed ID: 9653494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.
    Grillo-López AJ; White CA; Varns C; Shen D; Wei A; McClure A; Dallaire BK
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):66-73. PubMed ID: 10561020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.
    Maloney DG; Grillo-López AJ; White CA; Bodkin D; Schilder RJ; Neidhart JA; Janakiraman N; Foon KA; Liles TM; Dallaire BK; Wey K; Royston I; Davis T; Levy R
    Blood; 1997 Sep; 90(6):2188-95. PubMed ID: 9310469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of rituximab, the new FDA-approved antibody.
    Leget GA; Czuczman MS
    Curr Opin Oncol; 1998 Nov; 10(6):548-51. PubMed ID: 9818234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is the role of maintenance rituximab in follicular NHL?
    Maloney DG
    Oncology (Williston Park); 2008 Jan; 22(1):20-6; discussion 26, 29, 33-4. PubMed ID: 18251281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of B-cell lymphoma].
    Tobinai K
    Gan To Kagaku Ryoho; 2002 Mar; 29(3):473-80. PubMed ID: 11915743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
    Jazirehi AR; Bonavida B
    Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA approves new kind of lymphoma treatment. Food and Drug Administration.
    James JS; Dubs G
    AIDS Treat News; 1997 Dec; (No 284):2-3. PubMed ID: 11364912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases.
    Rastetter W; Molina A; White CA
    Annu Rev Med; 2004; 55():477-503. PubMed ID: 14746532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab: ongoing and future clinical development.
    Grillo-López AJ; Hedrick E; Rashford M; Benyunes M
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):105-12. PubMed ID: 11842397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma.
    King KM; Younes A
    Expert Rev Anticancer Ther; 2001 Aug; 1(2):177-86. PubMed ID: 12113023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
    Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
    J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibody therapy for B cell non-Hodgkin's lymphomas: emerging concepts of a tumour-targeted strategy.
    Buske C; Feuring-Buske M; Unterhalt M; Hiddemann W
    Eur J Cancer; 1999 Apr; 35(4):549-57. PubMed ID: 10492626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
    Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Newer treatments for non-Hodgkin's lymphoma: monoclonal antibodies.
    Maloney DG; Press OW
    Oncology (Williston Park); 1998 Oct; 12(10 Suppl 8):63-76. PubMed ID: 9830635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
    Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
    Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab: an insider's historical perspective.
    Grillo-López AJ
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):9-16. PubMed ID: 11226006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms.
    Harjunpää A; Junnikkala S; Meri S
    Scand J Immunol; 2000 Jun; 51(6):634-41. PubMed ID: 10849376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.